Bildkälla: Stockfoto

Spago Nanomedical: Second SPAGOPIX-01 dosing cohort fully recruited - Redeye

Redeye comments on Spago announcing full recruitment of the second dosing cohort of its phase I SPAGOPIX-01 trial with contrast agent SN132D in breast cancer. We are encouraged by today's news following unfortunate COVID-related delays for SPAGOPIX-01. The company expects interim result publication in early 2022, and we look forward to analyzing data from the second cohort at that point.

Redeye comments on Spago announcing full recruitment of the second dosing cohort of its phase I SPAGOPIX-01 trial with contrast agent SN132D in breast cancer. We are encouraged by today's news following unfortunate COVID-related delays for SPAGOPIX-01. The company expects interim result publication in early 2022, and we look forward to analyzing data from the second cohort at that point.
Börsvärldens nyhetsbrev
ANNONSER